ArticleEuropean journal of medical research2025
Interaction between IGF2BP3 and RP11-480I12.5 facilitates proliferation and suppresses apoptosis in non-small cell lung cancer.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNon-small cell lung cancer (NSCLC) is a malignant tumor type with the fastest growing incidence and mortality rates worldwide, accounting for over 80% of all lung cancer cases and presenting a substantial menace to human health. Abnormal expression of long non-coding RNAs has been linked to the advancement of NSCLC. RP11-480I12.5 is highly overexpressed in NSCLC, nevertheless its function remains unknown.
methodsqPCR was utilized to analyze the expression levels of RP11-480I12.5 in NSCLC cell lines. To elucidate the functional significance of RP11-480I12.5, H1650 and Calu-1 cells were infected with lentivirus carrying RP11-480I12.5-shRNA or IGF2BP3-shRNA. Subsequently, cell viability was assessed using the CCK-8 assay, cell proliferation capacity was evaluated through colony formation experiments, and apoptosis rates were determined using flow cytometry. The interactions between RP11-480I12.5 and IGF2BP3 were assessed through RNA‑binding protein immunoprecipitation assay (RIP) and RNA pull-down assays.
resultsRP11-480I12.5 was considerably increased in both the lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC) subtypes of NSCLC. IGF2BP3, which is extensively expressed in NSCLC, has poor predictive relevance, notably in LUAD. Interaction tests indicated a strong binding between RP11-480I12.5 and IGF2BP3, indicating a functional synergy in NSCLC pathogenesis. The co-regulated gene, WDHD1, which was considerably increased in NSCLC, facilitated the tumorigenic effects of the RP11-480I12.5-IGF2BP3 axis via influencing cell proliferation and death.
conclusionsRP11-480I12.5 interacted with IGF2BP3 to increase WDHD1 expression, promoting NSCLC cell proliferation and anti-apoptotic ability. Current findings elucidate how RP11-480I12.5 and IGF2BP3 interact at the molecular level, which has important implications for the progression of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.